Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 1.916 SEK 1.43% Market Closed
Market Cap: 351.9m SEK
Have any thoughts about
Cantargia AB?
Write Note

Intrinsic Value

CANTA's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one CANTA stock under the Base Case scenario is 0.877 SEK. Compared to the current market price of 1.916 SEK, Cantargia AB is Overvalued by 54%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CANTA Intrinsic Value
0.877 SEK
Overvaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cantargia AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CANTA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CANTA?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Cantargia AB

Provide an overview of the primary business activities
of Cantargia AB.

What unique competitive advantages
does Cantargia AB hold over its rivals?

What risks and challenges
does Cantargia AB face in the near future?

Summarize the latest earnings call
of Cantargia AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cantargia AB.

Provide P/S
for Cantargia AB.

Provide P/E
for Cantargia AB.

Provide P/OCF
for Cantargia AB.

Provide P/FCFE
for Cantargia AB.

Provide P/B
for Cantargia AB.

Provide EV/S
for Cantargia AB.

Provide EV/GP
for Cantargia AB.

Provide EV/EBITDA
for Cantargia AB.

Provide EV/EBIT
for Cantargia AB.

Provide EV/OCF
for Cantargia AB.

Provide EV/FCFF
for Cantargia AB.

Provide EV/IC
for Cantargia AB.

Show me price targets
for Cantargia AB made by professional analysts.

What are the Revenue projections
for Cantargia AB?

How accurate were the past Revenue estimates
for Cantargia AB?

What are the Net Income projections
for Cantargia AB?

How accurate were the past Net Income estimates
for Cantargia AB?

What are the EPS projections
for Cantargia AB?

How accurate were the past EPS estimates
for Cantargia AB?

What are the EBIT projections
for Cantargia AB?

How accurate were the past EBIT estimates
for Cantargia AB?

Compare the revenue forecasts
for Cantargia AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cantargia AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cantargia AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cantargia AB compared to its peers.

Compare the P/E ratios
of Cantargia AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Cantargia AB with its peers.

Analyze the financial leverage
of Cantargia AB compared to its main competitors.

Show all profitability ratios
for Cantargia AB.

Provide ROE
for Cantargia AB.

Provide ROA
for Cantargia AB.

Provide ROIC
for Cantargia AB.

Provide ROCE
for Cantargia AB.

Provide Gross Margin
for Cantargia AB.

Provide Operating Margin
for Cantargia AB.

Provide Net Margin
for Cantargia AB.

Provide FCF Margin
for Cantargia AB.

Show all solvency ratios
for Cantargia AB.

Provide D/E Ratio
for Cantargia AB.

Provide D/A Ratio
for Cantargia AB.

Provide Interest Coverage Ratio
for Cantargia AB.

Provide Altman Z-Score Ratio
for Cantargia AB.

Provide Quick Ratio
for Cantargia AB.

Provide Current Ratio
for Cantargia AB.

Provide Cash Ratio
for Cantargia AB.

What is the historical Revenue growth
over the last 5 years for Cantargia AB?

What is the historical Net Income growth
over the last 5 years for Cantargia AB?

What is the current Free Cash Flow
of Cantargia AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cantargia AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cantargia AB

Current Assets 114.2m
Cash & Short-Term Investments 104.7m
Receivables 1.2m
Other Current Assets 8.3m
Non-Current Assets 7.8m
PP&E 3.6m
Intangibles 4.2m
Current Liabilities 31.1m
Accounts Payable 11.5m
Accrued Liabilities 17.6m
Other Current Liabilities 2m
Non-Current Liabilities 278k
Other Non-Current Liabilities 278k
Efficiency

Earnings Waterfall
Cantargia AB

Revenue
0 SEK
Operating Expenses
-235.3m SEK
Operating Income
-235.3m SEK
Other Expenses
7.4m SEK
Net Income
-228m SEK

Free Cash Flow Analysis
Cantargia AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Cantargia reported exciting advancements in its CAN10 and nadunolimab (CAN04) clinical programs. The CAN10 program showed promising safety data and biomarker results in the Phase I trial, with plans to enter Phase II next year. Nadunolimab exhibited beneficial effects in pancreatic and triple-negative breast cancer trials, with a Phase IIb pancreatic cancer trial planned. Operational expenses decreased by 39% to SEK 85 million in the first half of the year, owing to reduced R&D costs. The company’s financial runway, with SEK 105 million in available funds, is expected to last until early next year.

What is Earnings Call?
Fundamental Scores

CANTA Profitability Score
Profitability Due Diligence

Cantargia AB's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Cantargia AB's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

CANTA Solvency Score
Solvency Due Diligence

Cantargia AB's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
59/100
Solvency
Score

Cantargia AB's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CANTA Price Targets Summary
Cantargia AB

Wall Street analysts forecast CANTA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CANTA is 9.894 SEK with a low forecast of 5.05 SEK and a high forecast of 14.7 SEK.

Lowest
Price Target
5.05 SEK
164% Upside
Average
Price Target
9.894 SEK
416% Upside
Highest
Price Target
14.7 SEK
667% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CANTA?

Click here to dive deeper.

Dividends

Cantargia AB
does not pay dividends
Shareholder Yield

Current shareholder yield for CANTA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Cantargia AB Logo
Cantargia AB

Country

Sweden

Industry

Biotechnology

Market Cap

351.9m SEK

Dividend Yield

0%

Description

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Contact

SKANE
Lund
Scheelevagen 27
+46462756260.0
www.cantargia.com

IPO

2015-03-17

Employees

24

Officers

Chief Executive Officer
Mr. Goran Forsberg
Founder & Scientific Advisor
Mr. Marcus Järås
Founder
Mr. Kjell Sjöström
Chief Financial Officer
Mr. Patrik Renblad
Chief Scientific Officer
Dr. David Liberg
Executive Assistant of Administration & Finance
Nina Valkama
Show More
Chief Medical Officer
Dr. Dominique Tersago
Chief Business Officer
Mr. Antonius Berkien
Financial Controller
Johanna Christensen
Show Less

See Also

Discover More
What is the Intrinsic Value of one CANTA stock?

The intrinsic value of one CANTA stock under the Base Case scenario is 0.877 SEK.

Is CANTA stock undervalued or overvalued?

Compared to the current market price of 1.916 SEK, Cantargia AB is Overvalued by 54%.

Back to Top